Oncobiologics, Inc. ( Oncobiologics)

Primary tabs

Oncobiologics's picture

Management

Contact Address

About Oncobiologics, Inc.

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology.

Oncobiologics press release, blog etc

Thu, 03/03/2022 - 06:32 Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
Thu, 02/24/2022 - 06:07 Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
Tue, 02/08/2022 - 04:54 Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
Wed, 01/19/2022 - 05:49 Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
Wed, 12/15/2021 - 03:57 Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia
Thu, 12/09/2021 - 03:05 Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
Mon, 11/29/2021 - 02:51 Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriters Option to Purchase Additional Shares
Tue, 11/23/2021 - 04:04 Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
Tue, 11/23/2021 - 03:18 Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
Sat, 11/13/2021 - 03:56 Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
Wed, 11/10/2021 - 04:57 Outlook Therapeutics to Present at the Virtual Investor Roundtable Event
Tue, 10/05/2021 - 16:22 Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Tue, 09/21/2021 - 18:26 Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Mon, 09/13/2021 - 11:13 Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
Wed, 08/11/2021 - 11:11 Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
Tue, 07/06/2021 - 20:01 Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
Mon, 06/14/2021 - 10:31 Outlook Therapeutics Announces Inclusion in the Russell 2000 Index
Tue, 06/08/2021 - 08:43 Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
more

InfoBox

HomePageoncobiologics.com
LinkedInwww.linkedin.com/company/oncobiologics-inc.